logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10034891 B1

PDFFull Text
Date of Patent:
Jul. 31, 2018

Filed:

May. 11, 2016

Inhibitors of diacylglycerol o-acyltransferase 1 (dgat-1) and uses thereof

Applicant:

Metabasis Therapeutics, Inc., La Jolla, CA (US);

Inventors:

K. Raja Reddy, San Diego, CA (US);

Jeff Stebbins, San Diego, CA (US);

Serge H. Boyer, San Diego, CA (US);

Mark D. Erion, Del Mar, CA (US);

Scott J. Hecker, Del Mar, CA (US);

Nicholas Brian Raffaele, San Diego, CA (US);

Brett C. Bookser, San Diego, CA (US);

Venkat Reddy Mali, Cupertino, CA (US);

Assignee:

Metabasis Therapeutics, Inc., San Diego, CA (US);

Attorney:

Knobbe Martens Olson & Bear LLP

Primary Examiner:

Jeffrey H Murray

Int. Cl.
CPC ...
A01N 43/82 (2006.01); A61K 31/41 (2006.01); A61K 31/675 (2006.01); A61K 31/542 (2006.01); A61K 31/52 (2006.01); A61K 31/662 (2006.01); A61K 31/665 (2006.01); A61K 45/06 (2006.01); C07D 473/16 (2006.01); C07D 473/34 (2006.01); C07D 473/40 (2006.01); C07F 9/30 (2006.01); C07F 9/32 (2006.01); C07F 9/653 (2006.01); C07F 9/6561 (2006.01); C07F 9/6574 (2006.01); C07F 9/48 (2006.01); C07F 9/655 (2006.01); A61K 31/683 (2006.01); A61K 31/688 (2006.01); C07F 9/40 (2006.01);
U.S. Cl.
CPC ...
A61K 31/675 (2013.01); A61K 31/52 (2013.01); A61K 31/542 (2013.01); A61K 31/662 (2013.01); A61K 31/665 (2013.01); A61K 31/683 (2013.01); A61K 31/688 (2013.01); A61K 45/06 (2013.01); C07D 473/16 (2013.01); C07D 473/34 (2013.01); C07D 473/40 (2013.01); C07F 9/303 (2013.01); C07F 9/3229 (2013.01); C07F 9/40 (2013.01); C07F 9/48 (2013.01); C07F 9/6552 (2013.01); C07F 9/6561 (2013.01); C07F 9/65312 (2013.01); C07F 9/65616 (2013.01); C07F 9/65742 (2013.01);
Abstract

The invention pertains to the use of compounds represented by the formula, Q-G-G-G-G-Z, where Q is The compounds can be used as diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease.

Find Patent Forward Citations

Loading…